A5020266520- Hepatitis C virus research
- Hepatitis B Virus Studies
- Liver Disease Diagnosis and Treatment
- HIV, Drug Use, Sexual Risk
- HIV/AIDS drug development and treatment
- Substance Abuse Treatment and Outcomes
- Opioid Use Disorder Treatment
- Homelessness and Social Issues
- Alcohol Consumption and Health Effects
UNSW Sydney
2020-2025
Point-of-care hepatitis C virus (HCV) RNA testing can facilitate single-visit diagnosis and treatment. This study evaluated a test treat intervention integrating point-of-care HCV testing, linkage to nursing care, peer-supported engagement/delivery of treatment among people with recent injecting drug use at peer-led needle syringe program (NSP).TEMPO Pilot is an interventional cohort (previous month) recruited between September 2019-February 2021 from one NSP in Sydney, Australia....
Monitoring of HCV-related morbidity and mortality is crucial to evaluate direct-acting antiviral (DAA) therapy impact HCV elimination progress. This population-based study examined among individuals with an notification in New South Wales (NSW), Australia, including cause-specific prior during the viral hepatitis era (2015-2021). notifications NSW, Australia (1995-2021) were linked hospitalisation records records. Over period 2002-2021, all-cause rates examined. Cox proportional hazard...
Xpert HCV Viral Load Fingerstick assay (Xpert VL FS) is a point-of-care test quantifying RNA in <1 hour, enabling same-visit diagnosis and treatment.This study evaluated time to detection using the FS assay. whole-blood samples were collected from participants an observational cohort Australia.In May 2018-2019, 1468 enrolled, 1426 had testing performed, 1386 valid result. was detected 23% (325/1386). Among people with undetectable (n = 1061), median result 57 minutes. detectable 325), 32...
Abstract Introduction Females of childbearing age with hepatitis C virus (HCV) face increased marginalisation intersecting, sex‐specific barriers to direct acting antiviral (DAA) therapy. We assessed the factors associated uptake DAA therapy among females age, including those evidence recent drug dependence. Methods HCV notifications in New South Wales, Australia (1995–2017) were linked opioid agonist (OAT), hospitalisations, incarcerations, perinatal, HIV notifications, deaths and...
People who inject drugs are at greater risk of hepatitis C virus (HCV) infection and hospitalization, yet admissions not utilized for HCV treatment initiation. We aimed to assess the extent which people with notification, including those evidence recent drug dependence, hospitalized while eligible direct-acting antiviral (DAA) therapy, uptake according hospitalization in DAA era.We conducted a longitudinal, population-based cohort study living era (March 2016-December 2018) through analysis...
New technologies and therapies allow the possibility of a single-visit test treat model for hepatitis C virus (HCV), addressing some barriers to care faced by people who inject drugs.The TEMPO Pilot Study was an interventional cohort study evaluating intervention among with recent injecting drug use at one peer-led needle syringe program (NSP) in Sydney, Australia between September 2019 February 2021. This analysis evaluated awareness HCV status agreement self-report RNA results. The also...
To evaluate a decentralised testing model and simplified treatment protocol of hepatitis C virus (HCV) infection to facilitate scale-up in Myanmar, this prospective, observational study recruited HIV–HCV co-infected outpatients receiving sofosbuvir/daclatasvir Yangon, Myanmar. The examined the outcomes factors associated with sustained virological response (SVR). A “hub-and-spoke” was evaluated where fingerstick capillary specimens were transported by taxi processed centrally. performance...
Objectives: There is limited research on health-related quality of life (HRQoL) among people who inject drugs (PWID).We evaluated the HRQoL and associated factors a cohort PWID in Australia. Methods: Participants were enrolled an observational study (the ETHOS Engage Study) May 2018 -September 2019 (Wave 1) November -June 2021 2).Participants completed EuroQol five-dimension five-level (EQ-5D-5L) survey at enrolment.Two-part models used to assess association clinical socioeconomic...
Abstract People living with HIV (PLHIV) are a priority population to receive hepatitis C virus (HCV) screening and treatment. We aimed characterize the HCV care cascade among PLHIV between 2010 2018 compare testing treatment uptake pre‐ post‐availability of direct‐acting antivirals (DAAs) in New South Wales (NSW), Australia. Records all notifications (1993–2017) were linked notifications, deaths, hospitalizations, incarcerations, opioid agonist therapy, RNA databases. Numbers proportions...
The primary aim of this study was to establish the feasibility implementing a larger RCT designed evaluate effect financial incentives on HCV treatment initiation among persons receiving opioid agonist therapy and/or who have injected drugs in prior six months. ETHOS Engage is an observational cohort participants recruited from drug and needle syringe programs Australia. Among 11 alcohol clinics, were RNA-positive randomized (1:1) receive standard care or AUD $60 gift card at initiation....
Background: Simplification and decentralisation of the treatment hepatitis C virus (HCV) infection is crucial for scale-up in low- middle-income countries (LMIC).Methods: This prospective, observational study recruited human immunodeficiency (HIV)-HCV co-infected outpatients receiving sofosbuvir/daclatasvir at hospitals Yangon, Myanmar. The examined outcomes using a simplified model care factors associated with sustained virological remission (SVR). evaluated utility decentralised...